Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: Inhibition significantly improves in vitro platelet quality after pathogen reduction treatment

Transfusion

Volumn 53, Issue 12, 2013, Pages 3164-3173

  Schubert, Peter ^a   Coupland, Danielle ^a   Culibrk, Brankica ^a   Goodrich, Raymond P ^a   Devine, Dana V ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PADGEM PROTEIN; PROTEIN KINASE B; RIBOFLAVIN; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ARTICLE; BLOOD SAFETY; DENSITOMETRY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; IN VITRO STUDY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; ULTRAVIOLET RADIATION;

BLOOD PLATELETS; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLATELET TRANSFUSION; RIBOFLAVIN; SIGNAL TRANSDUCTION; ULTRAVIOLET RAYS;

EID: 84890433682     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12173     Document Type: Article

References (45)

1. Hervig T, Seghatchian J, Apelseth TO,. Current debate on pathogen inactivation of platelet concentrates-to use or not to use? Transfus Apher Sci 2010; 43: 411-414.
2. Solheim BG, Seghatchian J,. The six questions of pathogen reduction technology: an overview of current opinions. Transfus Apher Sci 2008; 39: 51-57.
3. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP,. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877-885.
4. Goodrich RP, Gilmour D, Hovenga N, Keil SD,. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009; 49: 1205-1216.
5. Cardo LJ, Salata J, Mendez J, Reddy H, Goodrich RP,. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007; 37: 131-137.
6. Tonnetti L, Proctor MC, Reddy HL, Goodrich RP, Leiby DA,. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion 2010; 50: 1019-1027.
7. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP,. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335-1341.
8. Snyder E, Raife T, Lin L Cimino G, Metzel P, Rheinschmidt M, Baril L, Davis K, Buchholz DH, Corash L, Conlan MG,. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004; 44: 1732-1740.
9. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG,. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104: 1534-1541.
10. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, de, Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Metzel P, Buchholz D, Corash L,. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426-2433.
11. Cookson P, Thomas S, Marschner S, Goodrich RP, Cardigan R,. In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days. Transfusion 2012; 52: 983-994.
12. Ostrowski SR, Bochsen L, Windelov NA, Salado-Jimena JA, Reynaerts I, Goodrich RP, Johansson PI,. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2010; 51: 344-356.
13. Picker SM, Steisel A, Gathof BS,. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008; 48: 1685-1692.
14. Picker SM, Steisel A, Gathof BS,. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: results of a three-arm in vitro study. Transfus Apher Sci 2009; 40: 79-85.
15. Cid J, Escolar G, Lozano M,. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 2012; 103: 322-330.
16. Vamvakas EC,. Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang 2012; 102: 302-316.
17. Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van, Pampus LC, de, Greef GE, Luten M, Huijgens PC, Brand A, van, Rhenen DJ,. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150: 209-217.
18. van Marwijk Kooy M, Akkerman JW, van, Asbeck S, Borghuis L, van, Prooijen HC,. UVB radiation exposes fibrinogen binding sites on platelets by activating protein kinase C via reactive oxygen species. Br J Haematol 1993; 83: 253-258.
19. Verhaar R, Dekkers DW, De Cuyper IM, Ginsberg MH, de, Korte D, Verhoeven AJ,. UV-C irradiation disrupts platelet surface disulfide bonds and activates the platelet integrin alphaIIbbeta3. Blood 2008; 112: 4935-4939.
20. Schubert P, Culibrk B, Coupland D, Scammell K, Issa-Gyongyossy MI, Devine DV,. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage. Transfusion 2012; 52: 397-408.
21. Schubert P, Thon JN, Walsh GM, Chen CH, Moore ED, Devine DV, Kast J,. A signaling pathway contributing to platelet storage lesion development: targeting PI3-kinase-dependent Rap1 activation slows storage-induced platelet deterioration. Transfusion 2009; 49: 1944-1955.
22. Brass L,. Understanding and evaluating platelet function. Hematology Am Soc Hematol Educ Program 2010; 2010: 387-396.
23. Kato H, Takai S, Matsushima-Nishiwaki R, Adachi S, Minamitani C, Otsuka T, Tokuda H, Akamatsu S, Doi T, Ogura S, Kozawa O,. HSP27 phosphorylation is correlated with ADP-induced platelet granule secretion. Arch Biochem Biophys 2008; 475: 80-86.
24. Carvalho H, Alguero C, Santos M, de, Sousa G, Trindade H, Seghatchian J,. The combined effect of platelet storage media and intercept pathogen reduction technology on platelet activation/activability and cellular apoptosis/necrosis: Lisbon-RBS experience. Transfus Apher Sci 2006; 34: 187-192.
25. Picker SM, Oustianskaia L, Schneider V, Gathof BS,. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Vox Sang 2009; 97: 26-33.
26. Reid S, Johnson L, Woodland N, Marks DC,. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling. Transfusion 2012; 52: 2094-2103.
27. Reikvam H, Marschner S, Apelseth TO, Goodrich R, Hervig T,. The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution. Blood Transfus 2010; 8: 186-192.
28. Thiele T, Sablewski A, Iuga C, Bakchoul T, Bente A, Görg S, Völker U, Greinacher A, Steil L,. Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation-a LC-ESI-MS/MS-based proteomics approach. Blood Transfus 2012; 10: s63-70.
29. Kholodenko BN,. Four-dimensional organization of protein kinase signaling cascades: the roles of diffusion, endocytosis and molecular motors. J Exp Biol 2003; 206: 2073-2082.
30. Ichijo H,. From receptors to stress-activated MAP kinases. Oncogene 1999; 18: 6087-6093.
31. Nakagawa S, Ohtani T, Mizuashi M, Mollah ZU, Ito Y, Tagami H, Aiba S,. p38 Mitogen-activated protein kinase mediates dual role of ultraviolet B radiation in induction of maturation and apoptosis of monocyte-derived dendritic cells. J Invest Dermatol 2004; 123: 361-370.
32. Obata T, Brown GE, Yaffe MB,. MAP kinase pathways activated by stress: the p38 MAPK pathway. Crit Care Med 2000; 28: N67-77.
33. Van Laethem A, Van Kelst S, Lippens S, Declercq W, Vandenabeele P, Janssens S, Vandenheede JR, Garmyn M, Agostinis P,. Activation of p38 MAPK is required for Bax translocation to mitochondria, cytochrome c release and apoptosis induced by UVB irradiation in human keratinocytes. FASEB J 2004; 18: 1946-1948.
34. Li J, de Korte D, Woolum MD, Ruane PH, Keil SD, Lockerbie O, McLean R, Goodrich RP,. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004; 87: 82-90.
35. Li J, Lockerbie O, de, Korte D, Rice J, McLean R, Goodrich RP,. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 2005; 45: 920-926.
36. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, Kelly PN, Ekert PG, Metcalf D, Roberts AW, Huang DC, Kile BT,. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186.
37. Thon JN, Schubert P, Duguay M, Serrano K, Lin S, Kast J, Devine DV,. Comprehensive proteomic analysis of protein changes during platelet storage requires complementary proteomic approaches. Transfusion 2008; 48: 425-435.
38. Zhu Y, O'Neill S, Saklatvala J, Tassi L, Mendelsohn ME,. Phosphorylated HSP27 associates with the activation-dependent cytoskeleton in human platelets. Blood 1994; 84: 3715-3723.
39. Minuz P, Gaino S, Zuliani V, Tommasoli RM, Benati D, Ortolani R, Zancanaro C, Berton G, Santonastaso CL,. Functional role of p38 mitogen activated protein kinase in platelet activation induced by a thromboxane A2 analogue and by 8-iso-prostaglandin F2alpha. Thromb Haemost 2002; 87: 888-898.
40. Clifton AD, Young PR, Cohen P,. A comparison of the substrate specificity of MAPKAP kinase-2 and MAPKAP kinase-3 and their activation by cytokines and cellular stress. FEBS Lett 1996; 392: 209-214.
41. Prudent M, Crettaz D, Delobel J, Tissot JD, Lion N,. Proteomic analysis of Intercept-treated platelets. J Proteomics 2012; 76: 316-328.
42. Bender M, Eckly A, Hartwig JH, Elvers M, Pleines I, Gupta S, Krohne G, Jeanclos E, Gohla A, Gurniak C, Gachet C, Witke W, Nieswandt B,. ADF/n-cofilin-dependent actin turnover determines platelet formation and sizing. Blood 2010; 116: 1767-1775.
43. Pandey D, Goyal P, Dwivedi S, Siess W,. Unraveling a novel Rac1-mediated signaling pathway that regulates cofilin dephosphorylation and secretion in thrombin-stimulated platelets. Blood 2009; 114: 415-424.
44. Canault M, Duerschmied D, Brill A, Stefanini L, Schatzberg D, Cifuni SM, Bergmeier W, Wagner DD,. p38 mitogen-activated protein kinase activation during platelet storage: consequences for platelet recovery and hemostatic function in vivo. Blood 2010; 115: 1835-1842.
45. Wandall HH, Hoffmeister KM, Sorensen AL, Rumjantseva V, Clausen H, Hartwig JH, Slichter SJ,. Galactosylation does not prevent the rapid clearance of long-term, 4 degrees C-stored platelets. Blood 2008; 111: 3249-3256.